The estimated Net Worth of David Patience is at least $103 Thousand dollars as of 9 April 2024. David Patience owns over 37,468 units of Accelerate Diagnostics Inc stock worth over $102,581 and over the last few years David sold AXDX stock worth over $0.
David has made over 11 trades of the Accelerate Diagnostics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently David exercised 37,468 units of AXDX stock worth $60,323 on 9 April 2024.
The largest trade David's ever made was exercising 37,468 units of Accelerate Diagnostics Inc stock on 9 April 2024 worth over $60,323. On average, David trades about 3,149 units every 23 days since 2023. As of 9 April 2024 David still owns at least 63,715 units of Accelerate Diagnostics Inc stock.
You can see the complete history of David Patience stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON, AZ, 85714.
Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg, and Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.
accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.
Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include: